Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Consort, West Pharma Exubera alliance

This article was originally published in Clinica

Executive Summary

Consort Medical and West Pharmaceutical Services have ended their respective manufacturing and supply deals with Nektar Therapeutics for the Exubera insulin inhaler. Consort is set to receive £11m ($21.6m) from Nektar, while West Pharma did not disclose the amount that it would receive. San Carlos, California-based Nektar is required to pay Consort for reimbursement of costs and expenses under the terms of the original agreement, while West Pharma said that it would be reimbursed for facility, inventory, raw materials and personnel costs. Nektar holds the intellectual property to Exubera and the original agreement saw Consort (Milton Keynes, UK) and West Pharma (Lionville, Pennsylvania) manufacture the device. Manufacturing of the technology was ceased last October by Pfizer (who produced the insulin used in the devices) due to poor sales of the device. Analysts predicted last November that it would be Nektar, rather than Consort, West Pharma or Pfizer that would bear the brunt of the financial fallout from the ailing sales (see Clinica No 1279, p 12).

You may also be interested in...

US FDA Pharmaceutical Quality Office Lauds Continuous Manufacturing Approvals

The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.

Warning Letter Roundup & Recap – 19 February 2020

No device-related warning letters were released by the US FDA the week of 19 February.

Harmonization Needed For Complex And Value-Added Drugs

Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts